A Phase 1 interventional study of 14C-VX-993 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pain by Vertex Pharmaceuticals Incorporated — none open to participants now, none under way, none of them phase 3. Pain · Vertex Pharmaceuticals Incorporated.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 26th largest by enrollment, is one of 3 that started in 2025, is one of 24 in phase 1, and was the 23rd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 26 studies in Pain by Vertex Pharmaceuticals Incorporated is open now. The open studies under Pain, anywhere →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 39 across the 26 interventional studies. Of the 26 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of 14C-VX-993 after an overnight fast of at least 8 hours.
Drug: 14C-VX-993
Solution for Oral Administration.
Terminal Phase Rate Constant (λz) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Apparent Clearance (CL/F) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Maximum Observed Plasma Concentration (Cmax) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Time for VX-993 to Reach Maximum Concentration (Tmax) in Plasma
Time frame: From Day 1 up to Day 25
Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in Plasma
Time frame: From Day 1 up to Day 25
Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)
Time frame: Pre dose up to Day 25
AUC0-tlast of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
AUC0-inf of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
CL/F of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Renal Clearance (CLr) of TRA in Urine and Feces
Time frame: Pre dose up to Day 25
Cmax of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Fraction (percent) of Dose Excreted Unchanged in Urine of TRA
Time frame: Pre dose up to Day 25
Tmax of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma
Time frame: From Day 1 up to Day 25
Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and Feces
Time frame: From Day 1 up to Day 25
Metabolite Profiling and Identification in Plasma, Urine, and Feces
Time frame: From Day 1 up to Day 25
Terminal Phase Rate Constant (λz) of VX-993 Metabolites in Plasma and Urine (if applicable)
Time frame: From Day 1 up to Day 25
Amount of radioactivity excreted (Ae) of VX-993 Metabolites in Urine and Feces
Time frame: Pre dose up to Day 25
AUC0-last of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
AUC0-inf of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
CL/F of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
CLr of VX-993 Metabolites in Urine
Time frame: From Day 1 up to Day 25
Cmax of VX-993 Metabolites in Plasma
Time frame: From Day 1 up to Day 25
Fraction (percent) of Dose Excreted Unchanged in Urine of VX-993 Metabolites
Time frame: Pre dose up to Day 25
Tmax of VX-993 Metabolites in Plasma
Time frame: Day 1 up to Day 25
Apparent Volume of Distribution (Based on the Terminal Phase) of VX-993 Metabolites in Plasma
Time frame: Day 1 up to Day 25
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 35
Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses
Time frame: Pre-dose up to Day 35
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in May 2025, 1 month.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 1 month is below that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →